Leflunomide in treatment of RA patents preliminary estimation of therapeutical efficiency and side effects
Journal Title: Reumatologia - Year 2006, Vol 44, Issue 1
Abstract
In the preliminary estimation there were studied efficiency and safety of therapy leflunomid in patients with RA. The drug was given p. o. to a group of 158 patients (150 females and 8 males) for 3 days 100 mg/24 h, and then again 20 mg/24 h. The age of patients varied between 19-78 (average age was 55 years), with average duration time of the disease 10 years and 2 months. All of the patients were previously unsuccessfully treated with other DMARDS. All of the patients had high activity of disease estimated by DAS 28 ≥5.1 61.4% of patients were treated with long-term glicocorticosteroids. Time of trial was scheduled for 6 months. The therapeutical effect was initially estimated on the basis of a group of 43 patients who took the medicine for 91-120 days. Good and average therapeutical efficiency of treatment was observed in 76.73% of patients. Efficiency was expressed by lowering DAS 28 by 0.6-1.2 in a group of 11.62% of patients and 1.2 in a group of 65.11% of patients. In a group of 3.79% of patients the treatment was stopped because of complete lack of therapeutical effect. Frequency of side effects was initially estimated in a group of 158 patients. Treatment was interrupted in the group of 8.86% of patients because of such side effects as: diarrheas, elevation of transaminazes, leukopenia and trombocytopenia, skin changes and dizziness. Observations are continued. Preliminary results of observations allow for positive evaluation of treatment with leflunomid in RA patients.
Authors and Affiliations
Maria Rell-Bakalarska, Janusz Jaworski, Lidia Rutkowska-Sak, Małgorzata Wieczorek, Ewa Klimczak, Bożena Kowalczuk, Krzysztof Wojciech Rell
Keywords
Related Articles
- EP ID EP144333
- DOI -
- Views 50
- Downloads 0
Antinuclear antibodies in systemic sclerosis - antigen specificity and clinical significance
This article briefly reviews the structure and function of molecules targeted by specific for systemic sclerosis antinuclear antibodies. Moreover emphasizes ANA clinical relationships and methods of their detection.
Usefullness different antiphospholipid antibodies inthe assessment of the secondary antiphospholipid syndrome in lupus erythematosus patients - review and own experiences
The presence of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) is considered among diagnostic criteria of antiphospholipid syndrome (APS). Studies during the last decade revealed that also other antibodies...
Niesteroidowe leki przeciwzapalne – blaski i cienie
Działanie klasycznych niesteroidowych leków przeciwzapalnych polega na hamowaniu syntezy prostaglandyn przez blokowanie obu form enzymu cyklooksygenazy COX-1 i COX-2. Dla milionów ludzi NLPZ odgrywają ważną rolę w lecz...
Ponowne dojrzewanie odróżnicowanych w hodowlach in vitro chondrocytów w warunkach obniżonego stężenia tlenu
Degradacja chrząstki stawowej jest główną przyczyną zniszczenia stawów w wielu chorobach reumatycznych. Jedną z atrakcyjnych możliwości naprawy chrząstki jest jej regeneracja hodowanymi in vitro chondrocytami. Jednakże h...
Współistnienie ziarniniaka Wegenera i tocznia rumieniowatego układowego – opis przypadku z dyskusyjnym rozpoznaniem
Układowe zapalenia naczyń są heterogenną grupą chorób charakteryzującą się naciekiem z komórek zapalnych i martwicą ścian naczyń krwionośnych lub okolicy okołonaczyniowej. Są dominującym objawem wielu różnych jednostek k...